iBio receives patent allowance in China for lichenase fusion protein technology iBio reported the allowance of a Chinese patent on its lichenase fusion protein technology for therapeutic proteins and vaccines.
News For IBIO From The Last 14 Days
Check below for free stories on IBIO the last two weeks.
iBio enters into $10M stock repurchase agreement with Aspire Capital iBio announced it has entered into a common stock purchase agreement with Aspire Capital Fund. Within two business days of approval of the transaction by the NYSE MKT, Aspire Capital will complete an initial purchase of 1.14M shares of common stock at 44c per share, the closing sale price of iBio's common stock on the NYSE MKT on the business day prior to entry into the purchase agreement with Aspire Capital, for proceeds of $500,000. After the SEC declares a registration statement effective relating to the transaction, Aspire Capital has committed to purchase up to $9.5M in additional shares of common stock over a 24 month period. No warrants are associated with this agreement.